BR0315433A - Polimorfos de cloridreto de bicifadine - Google Patents

Polimorfos de cloridreto de bicifadine

Info

Publication number
BR0315433A
BR0315433A BR0315433-5A BR0315433A BR0315433A BR 0315433 A BR0315433 A BR 0315433A BR 0315433 A BR0315433 A BR 0315433A BR 0315433 A BR0315433 A BR 0315433A
Authority
BR
Brazil
Prior art keywords
bicifadine hydrochloride
polymorphs
crystalline form
hydrochloride polymorphs
bicifadine
Prior art date
Application number
BR0315433-5A
Other languages
English (en)
Inventor
Brenton William Russell
Rex Alwyn Shipplett
Kevin John Halloran
Original Assignee
Dov Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dov Pharmaceutical Inc filed Critical Dov Pharmaceutical Inc
Publication of BR0315433A publication Critical patent/BR0315433A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"POLIMORFOS DE CLORIDRETO DE BICITADINE". Trata-se de uma nova forma cristalina polimórfica de cloridreto de bicifadine, designada como forma B, a qual é mais termodinamicamente estável do que a forma polimórfica previamente conhecida de cloridreto de bicifadine, designada como forma A, métodos para a preparação da dita forma cristalina B e composições farmacêuticas que contêm a dita forma cristalina B.
BR0315433-5A 2002-11-08 2003-11-05 Polimorfos de cloridreto de bicifadine BR0315433A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42498202P 2002-11-08 2002-11-08
US10/702,397 US7094799B2 (en) 2002-11-08 2003-11-05 Polymorphs of bicifadine hydrochloride
PCT/US2003/035099 WO2004043920A1 (en) 2002-11-08 2003-11-05 Polymorphs of bicifadine hydrochloride

Publications (1)

Publication Number Publication Date
BR0315433A true BR0315433A (pt) 2005-08-30

Family

ID=32314565

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315433-5A BR0315433A (pt) 2002-11-08 2003-11-05 Polimorfos de cloridreto de bicifadine

Country Status (12)

Country Link
US (2) US7094799B2 (pt)
EP (1) EP1562900A4 (pt)
JP (1) JP2006519162A (pt)
KR (1) KR20050075382A (pt)
AU (1) AU2003286889A1 (pt)
BR (1) BR0315433A (pt)
CA (1) CA2504732A1 (pt)
MX (1) MXPA05004873A (pt)
NO (1) NO20052676L (pt)
PL (1) PL376604A1 (pt)
RU (1) RU2005117630A (pt)
WO (1) WO2004043920A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
PL376604A1 (pl) * 2002-11-08 2006-01-09 Dov Pharmaceuticals, Inc. Polimorfy chlorowodorku bicifadyny
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
CA2646729A1 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
US20070082939A1 (en) * 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
NZ592836A (en) 2005-07-27 2013-01-25 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US20090048233A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
WO2013040471A2 (en) * 2011-09-15 2013-03-21 Demerx, Inc. Noribogaine salt ansolvates
SG10201911417PA (en) 2015-06-17 2020-01-30 Otsuka America Pharmaceutical Inc Crystalline compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231935A (en) 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4196120A (en) * 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
GB1532682A (en) 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
PL376604A1 (pl) * 2002-11-08 2006-01-09 Dov Pharmaceuticals, Inc. Polimorfy chlorowodorku bicifadyny

Also Published As

Publication number Publication date
NO20052676L (no) 2005-08-03
EP1562900A1 (en) 2005-08-17
RU2005117630A (ru) 2006-01-20
PL376604A1 (pl) 2006-01-09
AU2003286889A1 (en) 2004-06-03
CA2504732A1 (en) 2004-05-27
NO20052676D0 (no) 2005-06-03
WO2004043920A8 (en) 2005-07-21
MXPA05004873A (es) 2005-12-05
JP2006519162A (ja) 2006-08-24
US20040102638A1 (en) 2004-05-27
US20070149599A1 (en) 2007-06-28
WO2004043920A1 (en) 2004-05-27
KR20050075382A (ko) 2005-07-20
US7094799B2 (en) 2006-08-22
EP1562900A4 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
BR0315433A (pt) Polimorfos de cloridreto de bicifadine
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
SG147466A1 (en) Thrombin receptor antagonists
MXPA05009367A (es) Antagonistas del receptor opioide.
NO20040794L (no) (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.
CY1119132T1 (el) Χρηση πολυολων για τη ληψη σταθερων πολυμορφων μορφων ριφαξιμινης
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
CY1122429T1 (el) Αμορφη υδροχλωρικη λερκανιδιπινη
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
WO2008005368A3 (en) Piperazines as p2x7 antagonists
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
UY26729A1 (es) Alquilaminas heterocíclicas como antagonistas de los receptores muscarínicos
TNSN08306A1 (fr) Imidazoles substitutes et leur utilisation comme pesticides
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ATE308522T1 (de) Opioidrezeptorantagonisten
SV2005001805A (es) 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735
NZ545580A (en) Aminoquinoline derivatives and their use as adenosine A3 ligands
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
PL1507531T3 (pl) Trwałe kompozycje farmaceutyczne desloratadyny
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
ES2194385T3 (es) Derivados del k-252a 3'-epimeros.
ECSP10010317A (es) Derivado 15,16-metilen-17-(1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.